Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 2
1995 2
1996 1
1997 1
1998 1
1999 2
2000 2
2003 1
2022 1
2023 2
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Gene expression signature predicts rate of type 1 diabetes progression.
Suomi T, Starskaia I, Kalim UU, Rasool O, Jaakkola MK, Grönroos T, Välikangas T, Brorsson C, Mazzoni G, Bruggraber S, Overbergh L, Dunger D, Peakman M, Chmura P, Brunak S, Schulte AM, Mathieu C, Knip M, Lahesmaa R, Elo LL; INNODIA Consortium. Suomi T, et al. EBioMedicine. 2023 Jun;92:104625. doi: 10.1016/j.ebiom.2023.104625. Epub 2023 May 22. EBioMedicine. 2023. PMID: 37224769 Free PMC article.
Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes.
Hendriks AEJ, Marcovecchio ML, Besser REJ, Bonifacio E, Casteels K, Elding Larsson H, Gemulla G, Lundgren M, Kordonouri O, Mallone R, Pociot F, Szypowska A, Toppari J, Berge TVD, Ziegler AG, Mathieu C, Achenbach P; INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group. Hendriks AEJ, et al. Diabetes Metab Res Rev. 2024 Feb;40(2):e3777. doi: 10.1002/dmrr.3777. Diabetes Metab Res Rev. 2024. PMID: 38375753
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes.
Van Rampelbergh J, Achenbach P, Leslie RD, Ali MA, Dayan C, Keymeulen B, Owen KR, Kindermans M, Parmentier F, Carlier V, Ahangarani RR, Gebruers E, Bovy N, Vanderelst L, Van Mechelen M, Vandepapelière P, Boitard C. Van Rampelbergh J, et al. BMC Med. 2023 May 24;21(1):190. doi: 10.1186/s12916-023-02900-z. BMC Med. 2023. PMID: 37226224 Free PMC article. Clinical Trial.
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers.
Van Rampelbergh J, Achenbach P, Leslie RD, Kindermans M, Parmentier F, Carlier V, Bovy N, Vanderelst L, Van Mechelen M, Vandepapelière P, Boitard C. Van Rampelbergh J, et al. BMC Med. 2024 Jun 21;22(1):259. doi: 10.1186/s12916-024-03476-y. BMC Med. 2024. PMID: 38902652 Free PMC article. Clinical Trial.
A future of AI-driven personalized care for people with multiple sclerosis.
Praet J, Anderhalten L, Comi G, Horakova D, Ziemssen T, Vermersch P, Lukas C, van Leemput K, Steppe M, Aguilera C, Kadas EM, Bertrand A, van Rampelbergh J, de Boer E, Zingler V, Smeets D, Ribbens A, Paul F. Praet J, et al. Among authors: van rampelbergh j. Front Immunol. 2024 Aug 19;15:1446748. doi: 10.3389/fimmu.2024.1446748. eCollection 2024. Front Immunol. 2024. PMID: 39224590 Free PMC article.
19 results